Literature DB >> 17291624

Lung cancer in systemic lupus erythematosus.

J Bin1, S Bernatsky, C Gordon, J-F Boivin, E Ginzler, D Gladman, P R Fortin, M Urowitz, S Manzi, D Isenberg, A Rahman, M Petri, O Nived, G Sturfeldt, R Ramsey-Goldman, A E Clarke.   

Abstract

BACKGROUND: Evidence points to a link between systemic lupus erythematosus (SLE) and an increased risk of lung cancer. Our objective was to provide a brief report of the lung cancer cases from an SLE cohort, with respect to demographics, histology, and exposures to smoking and immunosuppressive medications.
METHODS: Data were obtained from a multi-site international cohort study of over 9500 SLE patients from 23 centres. Cancer cases were ascertained through linkage with regional tumor registries.
RESULTS: We analyzed information on histology subtype for 30 lung cancer cases that had occurred across five countries. Most (75%) of these 30 cases were female, with a median age of 61 (range 27-91) years. In eight cases, the histological type was not specified. In the remainder, the most common histological type reported was adenocarcinoma (N=8; two of the adenocarcinomas were bronchoalveolar carcinoma) followed by small cell carcinoma (N=6), and squamous cell carcinoma (N=6) with one case each of large cell carcinoma and carcinoid tumor. Most (71%) of the lung cancer cases were smokers; only the minority (20%) had been previously exposed to immunosuppressive agents.
CONCLUSIONS: The histological distribution of the lung cancers from the SLE sample appeared similar to that of lung cancer patients in the general population, though the possibility of a higher proportion of more uncommon tumors (such as bronchoalveolar and carcinoid) cannot be excluded. A large proportion of the cancer cases were smokers, which is also not surprising. However, only a minority appeared to have been exposed to immunosuppressive agents. A large case-cohort study currently in progress should help shed light on the relative importance of these exposures in lung cancer risk for SLE patients.

Entities:  

Mesh:

Year:  2007        PMID: 17291624     DOI: 10.1016/j.lungcan.2007.01.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

Review 1.  Lung cancer mimicking systemic lupus erythematosus: case-based review.

Authors:  Jia Liu; Song Hu; Min Niu; Hua Wang; Yan Wang; Ning Tang; Bin Liu
Journal:  Rheumatol Int       Date:  2019-10-14       Impact factor: 2.631

2.  Cancer risk in systemic lupus: an updated international multi-centre cohort study.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke
Journal:  J Autoimmun       Date:  2013-02-12       Impact factor: 7.094

Review 3.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

4.  Malignancy in systemic lupus erythematosus: what have we learned?

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

Review 5.  Malignancies in systemic lupus erythematosus.

Authors:  Emese Kiss; Laszlo Kovacs; Peter Szodoray
Journal:  Autoimmun Rev       Date:  2009-07-27       Impact factor: 9.754

6.  Acceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease.

Authors:  Tomoyuki Kondo; Takaaki Tsunematsu; Akiko Yamada; Rieko Arakaki; Masako Saito; Kunihiro Otsuka; Satoko Kujiraoka; Aya Ushio; Mie Kurosawa; Yasusei Kudo; Naozumi Ishimaru
Journal:  Lab Invest       Date:  2016-01-25       Impact factor: 5.662

7.  Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study.

Authors:  D Dey; E Kenu; D A Isenberg
Journal:  Lupus       Date:  2013-07-15       Impact factor: 2.911

8.  Association between systemic lupus erythematosus and lung cancer: results from a pool of cohort studies and Mendelian randomization analysis.

Authors:  Haoxin Peng; Caichen Li; Xiangrong Wu; Yaokai Wen; Jinsheng Lin; Hengrui Liang; Ran Zhong; Jun Liu; Jianxing He; Wenhua Liang
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

9.  Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes.

Authors:  Satoshi Watanabe; Keigo Saeki; Yuko Waseda; Akari Murata; Hazuki Takato; Yukari Ichikawa; Masahide Yasui; Hideharu Kimura; Yasuhito Hamaguchi; Takashi Matsushita; Kazunori Yamada; Mitsuhiro Kawano; Kengo Furuichi; Takashi Wada; Kazuo Kasahara
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

10.  Lung cancer and interstitial lung diseases: a systematic review.

Authors:  Kostas Archontogeorgis; Paschalis Steiropoulos; Argyris Tzouvelekis; Evangelia Nena; Demosthenes Bouros
Journal:  Pulm Med       Date:  2012-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.